Ergomed Aktie - WKN: A117XM

NEWS:  European Mediscience Awards 2021. Ergomed has been shortlisted for “Best Communication Award” and “Company of the Year”.

http://www.mediscience-event.co.uk/nominations-overview/  

Notice of AGM and Annual Report
https://www.investegate.co.uk/ergomed-plc--ergo-/...105140700046079Y/  

M&A remains on the agenda with plenty of firepower

Ergomed has repeated on several occasions that it aims to expand via both organic top-line growth and M&A.

EdisonGroup: Ergomed Valuation: £683m or 1,400p/share

https://www.edisongroup.com/publication/...lar-2020-performance/29566  

Ergomed sees earnings ahead of expectations as chairman highlights strong start to 2021
https://www.proactiveinvestors.co.uk/companies/...to-2021-951909.html  

FY21e EBITDA ‘materially ahead’ of consensus
https://www.edisongroup.com/publication/...y-ahead-of-consensus/29610  

Fonds stockt weiter auf: https://www.investegate.co.uk/ergomed-plc--ergo-/...106171628132994C/  

ERGOMED WEBINAR - REGISTER NOW: With the webinar only 1 week away, make sure you register with the link below to join our expert speakers, Hyankova Jana and Marcela Fialova, as they guide you through Pharmacovigilance Agreements (PVAs).


https://www.bigmarker.com/...VL-WEBINAR-7-21-2021?show_live_page=true  

Ergomed plc - Trading Update
+Total revenue growth of 38.8% over H1 2020 to £56.0 million (up 48.1% in constant currency*)

+CRO division delivered strong growth with revenue up 90.7% over H1 2020 to £27.2 million, including the MedSource business acquired in 2020, with like-for-like growth of 16.1% (24.5% in constant currency)

https://www.proactiveinvestors.co.uk/LON:ERGO/Ergomed-PLC/rns/1010148  

Ergomed sees exceptional first half performance
https://www.proactiveinvestors.co.uk/companies/...ormance-956063.html  

Ergomed revenue jumps in first half amid new business wins
https://www.stockmarketwire.com/article/7211145/...business-wins.html  

Ergomed - executive interview
https://www.youtube.com/watch?v=rAu9IWSKsOc  

Momentum continues with EBITDA upgrades

https://www.edisongroup.com/publication/...with-ebitda-upgrades/29809  

Ergomed Interim results


   Total revenue growth of 38.8% over H1 2020 to £56.0 million (up 48.1% in constant currency*)
    djusted EBITDA of £12.1 million up 33.0%
   Basic adjusted earnings per share of 16.8p, up 48.7%
   Service fee revenue growth of 29.3% (11.1% on a like-for-like basis, 18.2% in constant currency*)
   CRO revenue up 90.2% over H1 2020 to £27.2 million, with like-for-like growth of 16.1% (up 24.5% in constant currency*)
   Net new sales awards in H1 2021 increased by 50.8% over H1 2020
   Growth in order book maintained - up 18.0% since 1 January 2021 (£193.0 million) and up 50.5% on prior year to £227.8 million, providing high visibility into H2 2021 and beyond
   Continued international expansion with growing presence in the USA
   North America revenues up 70.8% to £35.5 million with recent acquisitions Ashfield Pharmacovigilance and MedSource fully integrated
   Cash balance increased to £24.6 million and debt free

https://www.proactiveinvestors.co.uk/LON:ERGO/Ergomed-PLC/rns/1039549  

Ergomed reveal 'great progress on delivering on strategy in first half of 2021'
https://www.proactiveinvestors.co.uk/companies/...f-2021--961530.html  

US is now the biggest market in the mix

Ergomed has released its full H121 results. H121 revenue numbers were included in the trading update in July 2021, while the full accounts released last week provided details on profits. In the trading update, management also guided that FY21 adjusted EBITDA would be materially ahead of market expectations, which has since been discounted in the share price, hence last week’s announcement delivered no surprises. However, the key takeaway for us was that overall operational momentum continues to be strong, including the first three months of H221 (following the already stellar performance in FY20). In H121, Ergomed has also launched its expansion into the Japanese market. We have slightly increased our valuation to £751m or 1,536p/share (from 1,445p/share).

https://www.edisongroup.com/publication/...st-market-in-the-mix/30007  

Ergomed : Debra Kientop appointed as the new Vice President of Therapeutic Strategy for Oncology
https://www.marketscreener.com/quote/stock/...-for-Oncology-36596123/  

Navigating the Path Towards Decentralized Trials in Oncology: From Technology to AI", this hot topic webinar will occur on 18 November 2021.

https://www.bigmarker.com/...p;utm_campaign=november+2021+cro+webinar  

Ergomed (LON:ERGO) Presenting at the Proactive One2One virtual forum - October 2021 https://www.proactiveinvestors.co.uk/companies/...er-2021-964010.html  

???  

Soweit ich informiert bin, gibt es nur Edison, die Ergomed regelmäßig covern, aber diese Berichte sind auf Englisch - alle auf der Ergomed-Webseite zu finden.

Ich selbst bin vor ein paar Jahren über einen Artikel im Aktionär auf Ergomed aufmerksam geworden, aber das war 2019 und seitdem kam da auch nix mehr.

https://www.deraktionaer.de/artikel/...ie-rallye-weiter-20194148.html

Für aktuellere Artikel oder Meinungen wäre ich auch dankbar.
 

Ergomed to Present at Jefferies Conference 2021

https://www.investegate.co.uk/ergomed-plc--ergo-/...111150700073078S/  

US is now the biggest market in the mix

https://www.edisongroup.com/wp-content/uploads/...rket-in-the-mix.pdf  

Kursziel bei 1450p (17,00€)

https://www.sharecast.com/news/...ge-on-ergomed-at-buy--10293165.html  

Was geht hier heute ab ?
Warum heute 25% up ?

Mal sehen, ob das nachhaltig ist.
Bis dahin...
Nobby  

Übernahmeangebot für Ergomed durch Permira, 1350p pro Aktie, entspricht einem Aufschlag von ~26% zum letzten Schlusskurs.

https://www.research-tree.com/newsfeed/article/...-cash-offer-2010762